Full Text
EE129 Cost-Effectiveness of Ofatumumab Versus Ocrelizumab in Patients With Active Relapsing Multiple Sclerosis in Portugal

Abstract

Authors

N Gonçalves J Esparteiro M Machado C Ferreira T Guerreiro

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×